Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

First-Line Systemic Treatment for Advanced HCC

March 9th 2022

Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.

Phase 3 NuTide:121 Study Examining NUC-1031 in Biliary Tract Cancer to be Discontinued

March 8th 2022

The phase 3 NuTide:121 trial examining the first-in-class nucleotide analogue NUC-1031 in combination with cisplatin vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer is being discontinued.

Cetuximab–Radionuclide Functionalized Polymeric Nanocomplexes: A Radiopharmaceutical Perspective for Liver Cancer

March 2nd 2022

Liver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors.

Nivolumab/Ipilimumab Nears EU Approval for Frontline PD-L1+ Unresectable Advanced, Recurrent or Metastatic ESCC

February 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab and ipilimumab for use in the frontline treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with a PD-L1 expression of 1% or higher.

EU Panel Recommends Frontline Nivolumab/Chemo for PD-L1+ Unresectable Advanced, Recurrent or Metastatic ESCC

February 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the use of nivolumab in combination with chemotherapy in the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with a PD-L1 expression of 1% or higher.

Nearly 300 Novel Agents Currently in Development for Rare Cancers

February 24th 2022

New agents for rare cancers make up approximately 35% of drugs in the pipeline for all rare diseases, according to a report from the Pharmaceutical Research and Manufacturers of America.

Sotorasib Shows Early Promise in Heavily Pretreated KRAS G12C–Mutated Advanced Pancreatic Cancer

February 23rd 2022

Sotorasib had clinically meaningful activity in heavily pretreated patients with KRAS G12C–mutated advanced pancreatic cancer, according to findings from the phase 1/2 CodeBreaK 100 trial.

Potential Applications of ctDNA Testing in Colorectal Cancer

February 15th 2022

An overview of the ctDNA testing platforms and the potential clinical applications of ctDNA testing across the colorectal cancer disease continuum.

MRD Testing in Solid Tumors

February 15th 2022

The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.

From the Ground Up: Daniel G. Haller, MD, Gets Giants of Cancer Care Award in GI Cancer

February 11th 2022

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

Leading Investigator Seeks to Promote the Distinctions in GI Cancers

February 7th 2022

Michael A. Choti, MD, MBA, FACS, discusses the progress made in gastrointestinal cancers, plus the need to coordinate care between patients, oncologists, and surgeons.

2021 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2022

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Pelareorep/Atezolizumab Plus Chemo Shows Early Safety in Frontline Metastatic Pancreatic Cancer

February 3rd 2022

The 3-patient safety run-in for the pancreatic cancer cohort of the ongoing phase 1/2 GOBLET study did not reveal any safety concerns with the novel combination of pelareorep and atezolizumab.

Dr. Klempner on the Results of the DisTinGuish Trial in Advanced Gastroesophageal Adenocarcinoma

February 1st 2022

Sam Klempner, MD, discusses the results of the ongoing phase 2a DisTinGuish trial in advanced gastroesophageal adenocarcinoma.

Dr. Shah on the Potential Clinical Implications of the GLOW Trial in Claudin 18.2+/HER2- Gastric/GEJ Cancer

February 1st 2022

Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma.

Taking a Look Back at Trials From ASCO GI 2022

February 1st 2022

Reviewing some of the most talked about abstracts that were presented at the 2022 Gastrointestinal Cancers Symposium.

Future Directions for mCRC Management

January 27th 2022

Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.

Sequencing Therapy for Relapsed mCRC

January 27th 2022

Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.

Management of Relapsed mCRC

January 27th 2022

Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.

Dosing Strategies for Regorafenib for Patients With mCRC

January 27th 2022

Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.